Patient-friendly, non-technical summary of research papers

February 2026 Research Update

This report covers research on Mucopolysaccharidosis type I (Hurler syndrome) published in PubMed in February 2026. For other months, see all research updates.

Last update: May 19, 2026

At a glance

Nerve tests changed over years

In a very small treated group, repeated arm and hand nerve tests shifted in a worse direction over several years, showing that nerve function can continue to change over time.

Median nerve affected more

The median nerve showed more change than the ulnar nerve, which matches a carpal tunnel–type pattern and links nerve testing to hand symptoms.

Small study, variable outcomes

This long-term view suggests nerve measures may worsen over time despite disease-specific treatment, but the very small mixed group means it cannot predict what will happen for any one person.

Overview

This month, long-term nerve testing in the arms and hands showed worsening results over five years in a small treated group, suggesting that nerve problems in MPS I do not always stay stable even after enzyme replacement therapy and stem cell transplant. The overall direction was consistent: measures of nerve function moved in a worse direction over time, rather than leveling off.

The most repeated pattern was that the median nerve, often tied to carpal tunnel-type symptoms in the hand, seemed to change more than the ulnar nerve. The reported changes also pointed in two directions at once: damage to the nerve covering that helps signals travel quickly, and loss of the nerve fibers that carry the signal itself. In one person, the sensory signal from the median nerve could not be recorded later on both sides, which fits with more severe loss of detectable function.

A practical takeaway from these observations is that arm and hand symptoms in MPS I can be an ongoing, evolving part of the condition for some individuals, even when disease-specific treatment is already in place. The authors pointed to storage buildup and structural changes in tissues as possible reasons nerves might remain vulnerable to compression over time.

Because the evidence comes from only three patients and included MPS I and MPS II, how common this pattern is remains uncertain.

Get the monthly update by email

Subscribe here to receive an email when a new monthly Hurler syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).

Research topics this month

This month, a small long-term follow-up report suggested that nerve problems in the arms and hands can keep getting worse over several years in some people with MPS I, even while receiving enzyme replacement therapy (ERT) and after stem cell transplant (HSCT). The main pattern was ongoing damage affecting both the nerve covering (myelin) and the nerve fibers themselves, with the median nerve (often linked to carpal tunnel-type symptoms) seeming to be more affected than the ulnar nerve. For families, this adds a clearer picture that nerve symptoms may still change over time and may need ongoing attention in research and follow-up care.

Over 5 years of repeated nerve tests in three boys with MPS I or MPS II, the median nerve showed signs of worsening signal speed and shrinking signal size, which the authors interpreted as progressive demyelination and axonal loss. The sensory part of the median nerve appeared especially affected, and in one patient the sensory signal could not be recorded on both sides later on, suggesting more severe loss of detectable function. Changes were also seen in the ulnar nerve, but the progression was described as less pronounced than in the median nerve.

The authors discussed that MPS-related buildup of storage material and changes in bones and connective tissues could contribute to nerve compression and ongoing injury. In a few cases where additional muscle testing was possible, there were findings consistent with muscle changes related to nerve involvement. Taken together, this report frames upper-extremity neuropathy as something that may continue to evolve over time in MPS, rather than a problem that always stabilizes.

For patients and caregivers, the main message is that arm and hand nerve involvement in MPS I may continue to progress over years in some individuals, even when disease-specific treatments are being used. This does not prove what will happen for any one person, but it helps set expectations that symptoms like numbness, tingling, weakness, or loss of hand function may not be a one-time issue and may need repeated assessment over time. Because this was only 3 patients and included both MPS I and MPS II, it is mainly a research signal rather than a firm rule, and it cannot show how often this pattern occurs. Even so, it strengthens the idea that long-term tracking of nerve function is important for understanding day-to-day challenges and planning future studies aimed at preventing disability.

Limitations

The evidence comes from only three patients, so results cannot estimate how common progression is.
The group included both MPS I and MPS II, which limits how specifically findings apply to MPS I alone.
Without a larger comparison group, changes over time cannot be attributed to one factor with confidence.

Important information

This document summarizes recent research from PubMed-indexed publications using automated methods.
It is intended for educational purposes and does not replace medical advice.
Links to the original studies are provided via PubMed, where readers can explore abstracts and, when available, access full-text articles.
Some studies may include additional details that were not accessible for this summary.
Readers seeking more complete detail or context may find it helpful to review the original studies directly.